Study record · Cagrilintide
Once-weekly cagrilintide Phase II weight-management trial
Mean weight reductions ranged 6.0%-10.8% across cagrilintide doses versus 3.0% placebo; 4.5 mg produced 10.8% versus 9.0% with liraglutide.
Key result
Mean weight reductions ranged 6.0%-10.8% across cagrilintide doses versus 3.0% placebo; 4.5 mg produced 10.8% versus 9.0% with liraglutide.
Study details
Study designRandomized double-blind placebo- and active-controlled dose-ranging trial
PhasePhase II
PopulationAdults with overweight/obesity without diabetes
Sample size706
RouteSubcutaneous
Regimen / exposure0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly
Duration26 weeks
ComparatorPlacebo and liraglutide 3 mg daily
Primary endpoint / questionPercent body-weight change
Safety resultGI adverse events occurred in 41%-63% versus 32% placebo; nausea 20%-47% versus 18%.
Key limitationsPhase II; not the same evidence level as an approved weight-management medicine and not evidence for unregulated products.
Registry / identifierPMID 34798060 / NCT03856047